Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety

Publication date: June 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 2Author(s): Leena Halim, Adam Ajina, John MaherAbstractFollowing the landmark approvals by the United States Food and Drug Administration, the adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered mainstream clinical practice for patients with chemotherapy-resistant or refractory B-cell malignancies. These approvals have followed on from a prolonged period of pre-clinical evaluation, informing the design of clinical trials that have demonstrated unprecedented efficacy in this difficult to treat patient population. However, the delivery of autologous CAR-engineered T-cell therapy is complex, costly and not without significant risk. Here we summarize the key themes of CAR T-cell preclinical development and highlight a number of innovative strategies designed to further address toxicity and improve efficacy. In concert with the emerging promise of precision genome editing, it is hoped these next generation products will increase the repertoire of clinical applications of CAR T-cell therapy in malignant and perhaps other disease settings.

Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research